Edwards Lifesciences Corp — Director's Dealing 2021

May 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-05-07

Reporting Person: BOBO DONALD E JR (CVP,Strategy/Corp Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-07	Common Stock	M	11050.0000	$21.7600	Acquired	63894.8505	Direct
2021-05-07	Common Stock	S	3866.0000	$93.2259	Disposed	60028.8505	Direct
2021-05-07	Common Stock	S	7184.0000	$92.1382	Disposed	52844.8505	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-07	Employee Stock Option (Right to Acquire)	$21.7600	M	11050.0000	Disposed	2022-05-13	Common Stock (11050.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	38158.4268	Indirect
Common Stock	123820.0000	Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2021.

F2: This transaction was executed in multiple trades at prices ranging from $92.8600 to $93.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $91.8000 to $92.7900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F4: Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.